Pfizer (NYSE:PFE) Hits New 12-Month High – Still a Buy?

Pfizer Inc. (NYSE:PFE) hit a new 52-week high during trading on Wednesday. The stock traded as high as $29.27 and last traded at $29.1190, with a volume of 7,820,373 shares trading hands. The stock had previously closed at $28.37.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Sec61 drug-discovery partnership expands Pfizer’s pipeline: Pfizer agreed to collaborate with Enodia Therapeutics in a deal valued at up to $500 million to identify and advance small-molecule candidates targeting Sec61. Enodia will provide its proprietary discovery platform, while Pfizer will oversee clinical, regulatory and commercial development. The agreement gives Pfizer another potential source of medicines across multiple disease areas, although financial returns remain dependent on successful development. Pfizer partners with Enodia Therapeutics in $500m drug deal
• Positive Sentiment: Upcoming IDWeek presentations highlight infectious-disease research: Pfizer plans to present more than 50 abstracts, including 12 oral presentations, at the October 21–24 IDWeek 2026 conference. The data will cover prevention and treatment programs and could provide investors with updates on future growth products beyond declining COVID-related revenue. Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
• Positive Sentiment: Technical and earnings-estimate support: Pfizer recently moved above its 50-day moving average, while Erste Group Bank raised its 2026 EPS forecast slightly to $2.97 from $2.96. Pfizer also previously reported quarterly revenue and adjusted earnings above analyst expectations.
• Neutral Sentiment: Analyst stance remains cautious: J.P. Morgan maintained a Hold rating, suggesting that pipeline opportunities and valuation support are balanced by execution risks. J.P. Morgan Keeps Their Hold Rating on Pfizer
• Negative Sentiment: Dividend sustainability and patent risks remain overhangs: Commentary continues to flag Pfizer’s roughly 6% dividend yield, high payout ratio and upcoming patent expirations. Declining COVID-product sales also leave the company dependent on new launches and pipeline execution to sustain earnings growth.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Scotiabank boosted their target price on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday. BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.72.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a market capitalization of $166.75 billion, a price-to-earnings ratio of 38.48, a P/E/G ratio of 1.92 and a beta of 0.32. The company has a 50-day moving average of $27.81 and a 200-day moving average of $26.52.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.9%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its holdings in Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after purchasing an additional 745,213 shares during the period. Handelsbanken Fonder AB increased its stake in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after buying an additional 232,528 shares during the period. Leuthold Group LLC bought a new stake in shares of Pfizer during the 2nd quarter worth about $4,887,000. Park National Corp OH raised its position in shares of Pfizer by 332.1% during the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 186,053 shares in the last quarter. Finally, 111 Capital bought a new stake in shares of Pfizer during the 2nd quarter worth about $3,706,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.